KRAS mutation screening in colorectal cancer: From paper to practice

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 22-30

  Fakih, Marwan ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; EGFR; FOLFIRI; FOLFOX; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; COST CONTROL; GENE MUTATION; HUMAN; METASTASIS; MONOTHERAPY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; TUMOR BIOPSY; WILD TYPE;

EID: 77149176249     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.003     Document Type: Review

References (93)

1. Shankaran V, Wisinski KB, Mulcahy MF, et al. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008; 12:87-98.
2. Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res 2007; 13:6871s-6s.
3. Laurent-Puig P, Blons H, Cugnenc PH. Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 1999; 8(suppl 1):S39-47.
4. Denayer E, de Ravel T, Legius E, et al. Clinical and molecular aspects of RAS related disorders. J Med Genet 2008; 45:695-703.
5. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-4689
6. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-5327
7. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096
8. Colon cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2.2009. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/colon. pdf. Accessed: February 13, 2009.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767
10. Brink M, de Goeij AF, Weijenberg MP, et al. KRAS oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24:703-710
11. Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417
12. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-671
13. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572
14. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90:675-684
15. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308.
16. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(suppl):32S-40S.
17. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-2648
18. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102:1136-1141
19. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Kiras gene mutations in colorectal cancer. Gastroenterology 1993; 104:57-64.
20. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of KRAS mutations in colorectal carcinoma. Gastroenterology 1993; 104:1044-1048
21. Dix BR, Robbins P, Soong R, et al. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59:747-751
22. Andersen SN, Lovig T, Breivik J, et al. K-ras mutations and prognosis in largebowel carcinomas. Scand J Gastroenterol 1997; 32:62-69
23. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58:1149-1158
24. Tortola S, Marcuello E, Gonzalez I, et al. p53 and KRAS gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17:1375-1381
25. Esteller M, Gonzalez S, Risques RA, et al. KRAS and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299-304.
26. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 KRAS mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 KRAS mutations are associated with mucinous histotype. Ann Oncol 2002; 13:1438-1446
27. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85:692-696
28. Rougier P, Stroiakovski D, Kohne C, et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. Paper presented at: the ASCO Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract 443.
29. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-680
30. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664
31. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-2048
32. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995
33. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-1169
34. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-3237
35. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-515
36. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-5712
37. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379
38. Garm Spindler KL, Pallisgaard N, Rasmussen AA et al. The importance of KRAS mutations and EGF61A
39. Amado RG, Wolf M, Peeters M, et al. Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634
40. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
41. Di Fiore F, Van Cutsem E, Laurent-Puig P, et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. J Clin Oncol 2008; 26(15 suppl):186s (abstract 4035).
42. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma} RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-1129
43. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237
44. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-2319
45. Hayes VM, Westra JL, Verlind E, et al. New comprehensive denaturing-gradientgel-electrophoresis assay for KRAS mutation detection applied to paraffinembedded tumours. Genes Chromosomes Cancer 2000; 29:309-314
46. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005; 7:413-421
47. van Heek NT, Clayton SJ, Sturm PD, et al. Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 2005; 58:1315-1320
48. Hashimoto M, Barany F, Xu F, et al. Serial processing of biological reactions using flow-through microfluidic devices: coupled PCR/LDR for the detection of lowabundant DNA point mutations. Analyst 2007; 132:913-921
49. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26:1135-1145
50. Nollau P, Wagener C. Methods for detection of point mutations: performance and quality assessment. The IFCC Scientific Division, Committee on Molecular Biology Techniques. J Int Fed Clin Chem 1997; 9:162-170
51. Santiago FS, Todd AV, Hawkins NJ, et al. Detection of K-ras point mutation by enriched PCR-colorimetric plate assay. Mol Cell Probes 1997; 11:33-38
52. Poehlmann A, Kuester D, Meyer F, et al. K-ras mutation detection in colorectal cancer using the pyrosequencing technique. Pathol Res Pract 2007; 203:489-497
53. Marchetti A, Gasparini G. KRAS mutations and cetuximab in colorectal cancer. N Engl J Med 2009; 360:833-834
54. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple KRAS codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Clin Cancer Res 1991; 51:3497-3502
55. Conner BJ, Reyes AA, Morin C, et al. Detection of sickle cell beta S-globin allele by hybridization with synthetic oligonucleotides. Proc Natl Acad Sci U S A 1983; 80:278-282
56. Gundry CN, Vandersteen JG, Reed GH, et al. Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 2003; 49:396-406.
57. Juan T, Suggs S, Wolf M et al. A comparability study of 4 commercial K-RAS tests. Paper presented at: the 2008 American Association for Cancer Research annual meeting; April 12-16, 2008; San Diego, CA. Abstract 1811.
58. Roth AD, Tejpar S, Yan P, et al. Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. Paper presented at: the ASCO Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract 288.
59. Loupakis F, Pollina L, Stasi I, et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. J Clin Oncol 2008; 26(15 suppl):178s (abstract 4003).
60. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26:4217-4219
61. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13:1270-1275
62. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002; 161:1961-1971
63. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009; 7:45-53.
64. Chien CC, Chen SH, Liu CC, et al. Correlation of K-RAS codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC). Transl Res 2007; 149:96-102.
65. Haug U, Hillebrand T, Bendzko P, et al. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. Clin Chem 2007; 53:787-790
66. Mixich F, Ioana M, Voinea F, et al. Noninvasive detection through REMS-PCR technique of K-ras mutations in stool DNA of patients with colorectal cancer. J Gastrointestin Liver Dis 2007; 16:5-10.
67. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prev 2000; 24:1-12.
68. Heinzlmann M, Lang SM, Neynaber S, et al. Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. Eur J Gastroen terol Hepatol 2002; 14:1061-1066
69. Lindforss U, Zetterquist H, Papadogiannakis N, et al. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005; 25:657-661
70. Frattini M, Gallino G, Signoroni S, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008; 263:170-181
71. de Kok JB, van Solinge WW, Ruers TJ, et al. Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 1997; 57:601-604
72. Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 2004; 28:721-726
73. Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 2000; 46:1078-1084
74. Su YH, Wang M, Aiamkitsumrit B, et al. Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark 2005; 1:177-182
75. Su YH, Wang M, Brenner DE, et al. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci 2008; 1137:197-206.
76. Lev Z, Kislitsin D, Rennert G, et al. Utilization of K-ras mutations identified in stool DNA for the early detection of colorectal cancer. J Cell Biochem 2000; 34(suppl):35-39
77. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441-9442
78. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019
79. Folprecht G, Gruenberger T, Hartmann J, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Paper presented at: the ASCO Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract 296.
80. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69:1851-1857
81. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20:84-90.
82. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-1145
83. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286
84. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25:3238-3245
85. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19:717-723
86. Personeni N, Piessevaux H, Fieuws S, et al. Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab. J Clin Oncol 2008; 26(15 suppl):600s (abstract 11093).
87. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008; 14:5869-5876
88. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26:1427-1434
89. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345
90. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810
91. Lambrechts D, De Roock W, Prenen H, et al. The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27(15 suppl):173s (abstract 4020).
92. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15:3184-3188
93. Jonker DJ, Karapetis C, Harbinson C, et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-a phase III trial of cetuximab versus best supportive care (BSC). J Clin Oncol 2009; 27(15 suppl):172s (abstract 4016).